Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SITU announces a trio of new trials

OCTRU

SITU-NDORMS has announced the launch of three major new clinical trials. Funded by the NIHR, these studies are providing evidence for the treatment of chronic low back pain, knee osteoarthritis, and ACL injuries.

Patients can interrupt treatment of immune-supressing medicines for two-weeks in order to boost immunity provided by COVID-19 booster vaccine, finds major study

OCTRU

A major clinical trial, led by the University of Nottigham and managed by the Oxford Clinical trials Research Unit (OCTRU), has shown that people with inflammatory conditions are able to improve the antibody response from a COVID-19 booster vaccination by interrupting their treatment for two weeks immediately after having the vaccine.

Jonathan Cook made Professor of Clinical Trials and Medical Statistics

OCTRU

Jonathan Cook was successful in the 2023 University Recognition of Distinction exercise

OCTRU Pashion Study In the News

OCTRU

The ongoing PASHION study being ran by the Surgical Intervention Trials Unit group was in the BBC news last week.

Antibiotic bone cement found not to reduce infection after hip replacement

OCTRU

A large trial has found that using high-dose dual-antibiotic loaded cement is unlikely to reduce the risk of surgical site infection in people who have had a hip replacement.

Load More